Molecular targeted therapy of triple-negative breast cancer / 国际肿瘤学杂志

ABSTRACT

Treatment options are limited for triple negative breast cancer (TNBC)since endocrinother-apy and targeted therapy that aims directly at human epidermal growth factor receptor-2 (HER-2)are ineffec-tive.As such,in addition to surgical treatment,the mainstay of treatment of TNBC is systemic cytotoxic chemo-therapy.The targeted therapy of TNBC is becoming a research hotspot because of traditional chemotherapy cura-tive effect is not good enough.A large number of clinical trials have found that patients with TNBC can get ben-efits from targeted molecular strategies including poly-adenosine diphosphate glucose pyrophospheralase-ribose polymerase-1 (PARP-1 )inhibitor and epidermal growth factor receptor (EGFR)inhibitor.